Skip to content
MRD Watch

Sunday, November 15, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Lymphoma

Lymphoma.

AllMyelomaALLCLLAMLLymphoma

Must-know

  1. 1

    Pretreatment ctDNA and molecular response in aggressive lymphoma

    Kurtz et al. Journal of Clinical Oncology. 2018.

    Pretreatment ctDNA level and molecular response were independently associated with event-free survival and overall survival in aggressive lymphomas, including diffuse large B-cell lymphoma.

    PMID 30125215DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

    Presentations

    • Level 2prognosticASH Annual Meeting 2022

      Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

      Herrera, Alex F. · Abstract 1297 · POLARIX · paired baseline and Cycle 2 Day 1 results in 319/440 (Pola-R-CHP) and 299/439 (R-CHOP) patients

      AVENIO NHL CAPP-Seq; results as mean mutant molecules per mL

      Baseline ctDNA above the median MMPM was associated with shorter PFS and OS in both arms (Pola-R-CHP PFS HR 1.96, OS HR 2.17; R-CHOP PFS HR 1.43, OS HR 2.10). A log-fold change of at least 2.0 or undetectable ctDNA at C2D1 was reached by 66.8% and 65.6% of patients in the two arms and was prognostic (PFS HR 1.86 and 2.21). In Pola-R-CHP, a 2.5-log reduction (PFS HR 2.89) and C2D1 clearance (PFS HR 2.98, OS HR 2.74) remained prognostic independent of baseline risk factors.

    Trials

    • Recruiting · Phase 2

      NCT06050694 Glofitamab in a response-adapted approach using interim FDG-PET and ctDNA for primary therapy of DLBCL (GRAIL)

      Phase 2 feasibility trial of a ctDNA and FDG-PET interim response-adapted approach for primary therapy of diffuse large B-cell lymphoma. ClinicalTrials.gov lists the study as recruiting.

    • Recruiting · Phase 2

      NCT06828991 Mosunetuzumab consolidation for older patients with DLBCL and detectable ctDNA after pola-R-mini-CHP

      Phase 2 trial in which people with a radiographic complete response but detectable ctDNA receive mosunetuzumab, and those with undetectable ctDNA are observed. The registry primary outcome is the ctDNA clearance rate. ClinicalTrials.gov lists the study as recruiting.

    Regulatory timeline

      Lymphoma

      5 records

      • Level 2lymphomapositive2018

        Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

        Kurtz DM, Scherer F, Jin MC, Soo J, et al.. J Clin Oncol. PMID 30125215. CAPP-Seq ctDNA; early molecular response (EMR) and major molecular response (MMR) · n=217

        ctDNA dynamics from 217 patients at six centers, training and validation. Before therapy, ctDNA was detectable in 98%; pretreatment levels were prognostic in front-line and salvage settings. In the first validation set, front-line patients achieving EMR or MMR had superior 24-month EFS (EMR 83% vs 50%, P=0.0015; MMR 82% vs 46%, P<.001). EMR also predicted salvage 24-month EFS (100% vs 13%, P=0.011). Molecular response was independently prognostic including after adjustment for IPI and interim PET/CT. Level 2.

        Full text

      • Level 2lymphomapositive2025

        Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

        Roschewski M, Kurtz DM, Westin JR, Lynch RC, et al.. J Clin Oncol. PMID 40802906. ctDNA MRD for remission assessment in LBCL

        ctDNA used to assess remission in large B-cell lymphoma, evaluating residual disease after therapy. Level 2. Complements earlier Kurtz 2018 work.

        Full text

      • Level 2lymphomapositive2026

        Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

        Wang S, Nijland M, Strobbe L, Oosterveld M, et al.. J Clin Oncol. PMID 41385760. PhasED-Seq ctDNA MRD at end of first-line therapy · n=136

        Prospective HOVON-902 cohort, curative-intent first-line treatment. Phased-variant identification successful in 134 of 136 (99%). At end of treatment, 83% were MRD-negative and 17% MRD-positive. 3-year PFS 17% vs 85% (HR 9.8, 95% CI 5.1-19, P=9.63×10^-12); OS 43% vs 92% (HR 7.7, 95% CI 3.4-17.4, P=1.27×10^-6). MRD positivity had higher PPV for 2-year PFS than positive PET (68% vs 56%, P≤.001); NPV similar (89% vs 88%). This is not a POLARIX analysis. Level 2.

        Full text

      • Level 2lymphomapositive2026

        Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study

        Camus V, Krzisch D, Bruscaggin A, Lévêque E, et al.. Blood Adv. PMID 41979332. Interim ctDNA in PMBCL (LYSA, NCT04980222)

        Multicenter LYSA study of interim ctDNA assessment in primary mediastinal large B-cell lymphoma. MRD detection after frontline therapy strongly complemented PET response criteria in predicting outcome. Level 2.

        Full text

      • Level 2lymphomapositive2026

        Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation (TRANSFORM)

        Stepan L, Ansari S, Abramson JS, Okal A, et al.. J Clin Oncol. PMID 42044466. Ultrasensitive PhasED-Seq ctDNA at predefined time points · n=136

        Correlative ctDNA analysis of TRANSFORM (liso-cel vs salvage chemo + ASCT in second-line LBCL) in 136 patients. ctDNA clearance (MRD-neg) predicted longer EFS at all time points in both arms, with significantly more liso-cel-treated patients achieving MRD-neg. MRD-neg remained associated with EFS after adjusting for PET. Level 2.

        Full text

      No Hematologic updates are on file for this filter.